ANI Pharmaceuticals (NASDAQ:ANIP) Stock: Insider Nikhil Lalwani Sells 5,400 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani sold 5,400 shares of the company’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $71.89, for a total transaction of $388,206.00. Following the sale, the chief executive officer directly owned 333,689 shares in the company, valued at $23,988,902.21. This represents a 1.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nikhil Lalwani also recently made the following trade(s):

• On Tuesday, September 15th, Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $71.00, for a total transaction of $383,400.00.
• On Tuesday, August 25th, Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $74.30, for a total transaction of $401,220.00.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $72.29 on Friday. ANI Pharmaceuticals, Inc. has a 1 year low of $69.58 and a 1 year high of $97.00. The firm has a 50 day moving average of $73.59 and a 200-day moving average of $77.97. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. The stock has a market capitalization of $1.66 billion, a P/E ratio of 15.58, a price-to-earnings-growth ratio of 2.33 and a beta of 0.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%. The business had revenue of $266.04 million for the quarter, compared to the consensus estimate of $260.13 million. During the same period in the previous year, the business earned $1.80 EPS. ANI Pharmaceuticals’s revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ANIP has been the topic of a number of recent analyst reports. Leerink Partners assumed coverage on ANI Pharmaceuticals in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 price objective on the stock. Oppenheimer began coverage on ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They issued a “market perform” rating and a $85.00 target price for the company. Guggenheim cut their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a report on Monday, August 10th. Weiss Ratings cut ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Finally, Canaccord Genuity Group reduced their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Three research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $99.60.

Institutional Trading of ANI Pharmaceuticals

Several hedge funds have recently modified their holdings of ANIP. USA Financial Formulas acquired a new stake in shares of ANI Pharmaceuticals in the third quarter valued at approximately $39,000. GAMMA Investing LLC raised its position in ANI Pharmaceuticals by 13.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,783 shares of the specialty pharmaceutical company’s stock worth $130,000 after purchasing an additional 211 shares during the last quarter. Versant Capital Management Inc lifted its holdings in ANI Pharmaceuticals by 103.3% during the 3rd quarter. Versant Capital Management Inc now owns 427 shares of the specialty pharmaceutical company’s stock worth $31,000 after buying an additional 217 shares in the last quarter. Tidal Investments LLC acquired a new position in ANI Pharmaceuticals during the 2nd quarter worth $248,000. Finally, WINTON GROUP Ltd acquired a new position in ANI Pharmaceuticals during the 2nd quarter worth $4,558,000. 76.05% of the stock is owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes branded and generic prescription medicines. The company focuses on products with complex formulations, difficult-to-manufacture dosage forms and limited competition, serving therapeutic areas that include rare diseases, ophthalmology, endocrinology, central nervous system conditions and other specialty markets.

ANI’s portfolio includes Cortrophin Gel (repository corticotropin injection), a specialty therapy used for certain inflammatory and autoimmune conditions, as well as a range of established brand and generic products.